Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D3.399 - An SYK Variant with Variable Spectrum of Immunodeficiency and Immune Dysregulation: Case Series
D3.409 - Immunological Mechanisms in Treatment-Resistant Depression
D3.413 - Basophil Activation Test Positivity and Response to Ciclosporin in Chronic Spontaneous Urticaria: A Real-World Exploratory Study
D3.414 - Clinical and Laboratory Predictors of Basophil Activation Test Positivity in Chronic Spontaneous Urticaria: A Real-World Exploratory Study
D3.416 - PEG-CUR Reduces Oxidative Stress and Total Methylation Induced by Cigarette Smoke in Epithelial Cells: Development of PEG-Curcumin Loaded Fast-Dissolving Microneedle Patches
D3.398 - Primary Care Physicians’ Perspectives on Primary Immunodeficiency Diseases
D3.401 - A mechanism for loss of biodiversity in the gut: Toxic effects and metabolic alterations of food additives on human fecal microbiome
D3.402 - Evaluation of Apigenin's Anti-Inflammatory and Wound Healing Effects Using Atopic Dermatitis Cell Culture Model
D3.403 - Protein Profiling of CAR-Engineered NK92-Derived Exosomes Using Western Blot
D3.404 - From CVID to CTLA-4 Haploinsufficiency: The Impact of Genetic Diagnosis on Targeted Therapy
D3.406 - Novel bone materials selectively modulate the human immune response to favor remodeling over acute inflammation
D3.407 - Angioedema: cause or consequence?
D3.408 - When Angioedema Is Not Angioedema: EBV-Associated Lymphocytic Inflammation Mimicking Hereditary Angioedema
D3.415 - Galectin-10 Expression in Plasma-Derived Extracellular Vesicles of Patients with Eosinophilic Esophagitis: a Pilot Study
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download